文献速递前列腺癌

盆腔廓清术治疗局部晚期症状性去势敏感及去势抵抗性前列腺癌

Pelvic exenteration surgery in patients with locally advanced castration-naïve and castration-resistant, symptomatic prostate cancer.
PubMed 文献 · BJU Int · 2020-05-16

该回顾性研究评估了103例局部晚期症状性去势敏感或去势抵抗性前列腺癌患者接受盆腔廓清术(PES)的手术、症状及肿瘤学结局。中位随访36.5个月,1年和3年无症状生存率分别为89.2%和64.1%,中位无症状生存27.9个月;1年和3年总生存率分别为92.2%和43.7%,中位总生存33.6个月。Clavien-Dindo 2、3、4级并发症分别发生于31例(30.6%)、12例(11.6%)和8例(8.1%)。结论认为PES在精选患者中技术可行,>90%患者症状缓解,覆盖80%剩余 lifetime。

要点

  • PES在精选的局部晚期症状性前列腺癌患者中技术可行,可显著缓解症状。
  • 1年和3年无症状生存率分别为89.2%和64.1%,中位无症状生存27.9个月。
  • 1年和3年总生存率分别为92.2%和43.7%,中位总生存33.6个月。

核心结论

  • 盆腔廓清术在经选择的局部晚期症状性去势敏感或去势抵抗性前列腺癌患者中技术可行,>90%患者症状缓解,覆盖80%剩余 lifetime。

研究设计与样本

  • 回顾性评估103例局部晚期进展且有症状的去势敏感或去势抵抗性前列腺癌患者接受盆腔廓清术(PES)的手术、症状和肿瘤学结局。
  • 术式包括根治性膀胱前列腺切除术71例(68.9%)、根治性前列腺切除加可控性膀胱造口9例(8.7%)、全盆腔廓清术23例(22.3%)。
  • 所有患者行MRI、膀胱镜和直肠镜局部分期,胸腹盆CT和骨扫描系统分期;并发症按Clavien-Dindo分级评估;采用Kaplan-Meier法评估无症状生存和总生存。

主要发现

  • 中位随访36.5(范围3-123)个月,1年和3年无症状生存率分别为89.2%(n=89)和64.1%(n=66),中位无症状生存27.9个月。
  • 78.6%的患者在剩余 lifetime 内保持无症状。
  • 1年和3年总生存率分别为92.2%和43.7%,中位总生存33.6个月。
  • Clavien-Dindo 2、3、4级并发症分别发生于31例(30.6%)、12例(11.6%)和8例(8.1%)。

临床怎么用

  • 对于经严格选择的局部晚期症状性去势敏感或去势抵抗性前列腺癌患者,可考虑盆腔廓清术以缓解症状。

局限性

  • 本研究为回顾性设计,样本来自单中心或有限中心,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate retrospectively the surgical, symptomatic and oncological outcomes of pelvic exenteration surgery (PES) in men with significant intrapelvic complications of locally advanced castration-sensitive (CSPC) and castration-resistant prostate cancer (CRPC). PATIENTS AND METHODS: A total of 103 patients with locally advanced progressive and symptomatic CSPC or CRPC underwent PES (radical cystoprostatectomy, n = 71 [68.9%]; radical prostatectomy with continent vesicostomy, n = 9 [8.7%]; total exenteration, n = 23 [22.3%]). All patients underwent local staging via magnetic resonance imaging, cystoscopy and rectoscopy. Systemic staging was carried out with chest, abdominal and pelvic computed tomography scans and bone scans. Peri-operative complications were assessed according to Clavien-Dindo classification. Symptom-free and overall survival were evaluated using the Kaplan-Meier method. Statistical tests were two-tailed with a P value <0.05 taken to indicate statistical significance. RESULTS: After a median (range) follow-up of 36.5 (3-123) months, the symptom-free survival rate at 1 and 3 years was 89.2% (n = 89) and 64.1% (n = 66), respectively. The median symptom-free survival was 27.9 months. A total of 78.6% of the patients were symptom-free during their remaining lifetime. The overall survival rate at 1 and 3 years was 92.2% and 43.7%, respectively, and the median overall survival was 33.6 months. Clavien-Dindo grades 2, 3 and 4 complications developed in 31 (30.6%), 12 (11.6%) and eight patients (8.1%), respectively. CONCLUSION: Pelvic exenteration surgery is technically feasible in well-selected patients, resulting in symptom relief in >90% of patients, covering 80% of their remaining lifetime.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Heidenreich A, Bludau M, Bruns C, et al. Pelvic exenteration surgery in patients with locally advanced castration-naïve and castration-resistant, symptomatic prostate cancer. BJU Int. 2020. PMID: 32320130. doi:10.1111/bju.15088

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。